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The cblD defect of intracellular vitamin B12 metabolism can lead to isolated methylmalonic aciduria (cblD-
MMA) or homocystinuria (cblD-HC), or combined methylmalonic aciduria and homocystinuria (cblD-MMA/
HC). We studied the mechanism whereby MMADHC mutations can lead to three phenotypes. The effect of
various expression vectors containing MMADHC modified to contain an enhanced mitochondrial leader se-
quence or mutations changing possible downstream sites of reinitiation of translation or mutations introdu-
cing stop codons on rescue of adenosyl- and methylcobalamin (MeCbl) formation was studied. The
constructs were transfected into cell lines derived from various cblD patient’s fibroblasts. Expression of
10 mutant alleles from 15 cblD patients confirmed that the nature and location of the mutations correlate
with the biochemical phenotype. In cblD-MMA/HC cells, improving mitochondrial targeting of MMADHC clear-
ly increased the formation of adenosylcobalamin (AdoCbl) with a concomitant decrease in MeCbl formation.
In cblD-MMA cells, this effect was dependent on the mutation and showed a negative correlation with en-
dogenous MMADHC mRNA levels. These findings support the hypothesis that a single protein exists with
two different functional domains that interact with either cytosolic or mitochondrial targets. Also a delicate
balance exists between cytosolic MeCbl and mitochondrial AdoCbl synthesis, supporting the role of cblD
protein as a branch point in intracellular cobalamin trafficking. Furthermore, our data indicate that the se-
quence after Met116 is sufficient for MeCbl synthesis, whereas the additional sequence between Met62
and Met116 is required for AdoCbl synthesis. Accordingly, western blot studies reveal proteins of the size
expected from the stop codon position with subsequent reinitiation of translation.
INTRODUCTION
In mammals, vitamin B12 (cobalamin) is essential for normal
development and survival and must be provided in the diet
from animal products or from supplements. It is converted
intracellularly to two active coenzyme forms, adenosylcobala-
min (AdoCbl) and methylcobalamin (MeCbl). AdoCbl is the
coenzyme for mitochondrial methylmalonyl-CoA mutase
(MCM) which converts L-methylmalonyl-CoA to succinyl-
CoA and is involved in catabolism of odd-chain fatty acids
and some amino acids. Deficiency of MCM (MIM 609058)
leads to accumulation of methylmalonic acid in body fluids
(1) and results in a severe clinical phenotype. MeCbl is the co-
enzyme for cytosolic methionine synthase (MS) which con-
verts homocysteine to methionine and is essential for normal
one-carbon metabolism (2). Deficiency of MS (MIM
156570) causes increased levels of homocysteine in body
fluids and a severe neurological phenotype.
Vitamin B12 has to be converted to its active cofactors in a
series of intracellular reactions defined as eight different
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complementation classes (cblA, cblB, cblC, cblD composed of
the three subgroups cblD-MMA, cblD-HC and cblD-MMA/
HC, cblE, cblF, cblG and mut) (3–5). The cblC, cblD-
MMA/HC and cblF disorders cause combined methylmalonic
aciduria and homocystinuria (MMA/HC), cblA, cblB, cblD-
MMA and mut cause isolated MMA and cblD-HC, cblE,
and cblG result in isolated HC.
We previously reported that the cblD defect is associated
with three distinct biochemical phenotypes: deficient synthesis
of either both cobalamin coenzymes or only MeCbl or AdoCbl
(5). Using microcell-mediated chromosome transfer and
refined genetic mapping, we identified the gene responsible
for cblD as MMADHC (methylmalonic aciduria, cblD type
and homocystinuria) (3). Individuals with cblD-MMA carry
a mutation causing a premature stop of translation toward
the N-terminal part of the protein on at least one allele, and
patients with cblD-HC carry missense mutations causing
amino acid substitutions toward the C-terminal part of the
protein. The combined phenotype is associated with deleteri-
ous nonsense and missense mutations in the middle of the
protein (3).
Clinical presentation is variable: cblD-MMA/HC patients
presented with developmental delay, seizures, hypotonia, leth-
argy and megaloblastic anemia, cblD-HC patients with devel-
opmental delay, ataxia and megaloblastic anemia and
cblD-MMA patients had respiratory distress, cranial hemor-
rhage, seizures and an abnormal electroencephalogram (3,5).
We have speculated that in patients with cblD-MMA, there
is reinitiation of translation whereby Met62 acts as second
start codon. In patients with cblD-HC, we showed that the mis-
sense mutations in the C-terminal part affect MeCbl formation
but not the functional domain for the synthesis of AdoCbl (3).
In this study, we have characterized mutations in further
patients, performed transfection studies using different
mutant constructs and investigated wild-type and mutant pro-
teins by western blot analysis in order to elucidate the molecu-
lar mechanisms of the three different phenotypes of cblD.
RESULTS
Mutations detected in cblD patients
Table 1 summarizes the phenotype, and nucleotide and protein
changes in the 10 patients previously reported and 7 new ones
(3,6). Of a total of 15 mutations, two, c.133dupG and
c.229dupG, have not been reported.
Expression studies of mutant alleles
The effect of mutant alleles on MeCbl and AdoCbl synthesis was
studied in an immortalized combined cblD-MMA/HC cell line
(D007) confirming the functional significance of various muta-
tions (Supplementary Material, Fig. S1). We show that mutant
alleles associated with the cblD-HC phenotype (c.737A.G,
p.D246G; c.746A.G, p.Y249C; c.776T.C, p.L259P) were
unable to rescue MeCbl synthesis. In contrast, MeCbl synthesis
was clearly rescued by mutant alleles associated with the cblD-
MMA phenotype (c.57_64del, p.S20X; c.60insAT, p.L21IfsX2;
c.133dupG, p.A45GfsX15; c.160C.T, p.R54X; c.228dupG,
p.N77EfsX5). Regarding AdoCbl synthesis, mutant alleles asso-
ciated with cblD-HC clearly rescued AdoCbl synthesis. The mis-
sense allele c.545C.A (p.T182N) found in a patient with
cblD-HC compound heterozygous for the cblD-HC allele
c.746A.G rescued neither MeCbl nor AdoCbl synthesis. The
Table 1. Phenotype and MMADHC mutations detected in 17 patients from 16 families with cblD defect
Allele 1 Allele 2
Phenotypea ID Nucleotide change Protein
(predicted)
Location Nucleotide change Protein
(predicted)
Location Reference
MMA D003 c.57_64delCTCTTTAG p.S20X Exon 3 c.57_64delCTCTTTAG p.S20X Exon 3 Pat 3 in Coelho et al. (3)
MMA D010 c.57_64delCTCTTTAG p.S20X Exon 3 c.57_64delCTCTTTAG p.S20X Exon 3 This study
MMA D008 c.60insAT p.L21IfsX2b Exon 3 c.455dupCc p.C153MfsX10 Exon 5 WG3280 in Miousse et al. (6)
MMA D012 c.133dupG p.A45GfsX15 Exon 3 c.133dupG p. A45GfsX15 Exon 3 This study
MMA D004 c.160C.T p.R54Xb Exon 4 c.307_324dupc p.L103_S108dup Exon 4 Pat 4 in Coelho et al (3),
WG1437 in Miousse et al.
(6)
MMA D017 c.228dupG p.N77EfsX5 Exon 4 c.228dupG p.N77EfsX5 Exon 4 This study
HC D011 c.737A.G p.D246G Exon 8 c.737A.G p.D246G Exon 8 WG3745 in Miousse et al. (6)
HC D015 c.737A.G p.D246G Exon 8 c.737A.G p.D246G Exon 8 This study
HC D013d c.746A.G p.Y249C Exon 8 c.746A.G p.Y249C Exon 8 This study
HC D014d c.746A.G p.Y249C Exon 8 c.746A.G p.Y249C Exon 8 This study
HC D002 c.746A.G p.Y249C Exon 6 c.545C.A p.T182N Exon 8 Pat 2 in Coelho et al. (3)
HC D001 c.776T.C p.L259P Exon 8 c.776T.C p.L259P Exon 8 Pat. 1 in Coelho et al. (3)
MMA/HC D006 c.419dupA p.Y140X Exon 5 c.419dupA p.Y140X Exon 5 Pat 6 in Coelho et al. (3)
MMA/HC D009 c.683C.G p.S228X Exon 7 c.683C.G p.S228X Exon 7 WG3583 in Miousse et al. (6)
MMA/HC D007 c.696+1_4delGTGA p.F204_A232del
(skip exon 7)
Intron 7 c.696+1_4delGTGA p.F204_A232del
(skip exon 7)
Intron 7 Pat 7 in Coelho et al. (3)
MMA/HC D005 c.748C.T p.R250X Exon 8 c.748C.T p.R250X Exon 8 Pat 5 in Coelho et al (3)
MMA/HC D016 c.748C.T p.R250X Exon 8 c.748C.T p.R250X Exon 8 This study
aMMA, isolated methylmalonic aciduria; HC, isolated homocystinuria; MMA/HC, combined methylmalonic aciduria and homocystinuria.
bAppears homozygous at cDNA level; clearly heterozygous at genomic level.
cNot detectable at cDNA level suggesting low steady-state levels of mRNA; clearly heterozygous at genomic level.
dSiblings.
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nonsense allele c.683C.G (p.S228X), identified in the homozy-
gous state in a combined defect patient, was used as a negative
control.
Rescue of AdoCbl synthesis in cblD-MMA/HC and
cblD-MMA cells
In previous studies, we showed that AdoCbl synthesis was
poorly corrected by transfection with the wild-type allele,
except when using a vector in which a V5-polypeptide was
attached to the C-terminus of the wild-type protein (3). We
hypothesized that the low efficiency of rescue of AdoCbl syn-
thesis by the wild-type construct is caused by inefficient mito-
chondrial targeting. Analysis of the amino acid sequence of
MMADHC by the Mitoprot II software (7) predicted a cleav-
able, N-terminal mitochondrial leader sequence (MLS) of 11
amino acids (MANVLCNRARL).
To investigate the efficiency of the endogenous MLS, we
prepared a construct (cblD_MLS_ALDH2) in which this puta-
tive MLS (Met1-Leu11) was replaced by the MLS of aldehyde
dehydrogenase 2 (ALDH2, NP_000681) which has been
shown previously to efficiently target natural and synthetic
polypeptides to the mitochondria (8). Transfection of this con-
struct into a combined defect cell line (D007,
p.F204_A232del/p.F204_A232del) led to a dramatic increase
in AdoCbl synthesis to high normal or elevated levels
(Fig. 1), and a concomitant decrease in the level of rescue
of MeCbl synthesis.
In contrast, in different cell lines from patients with isolated
cblD-MMA, transfection with either cblD wild-type or even
cblD_MLS_ALDH2 did not normalize AdoCbl synthesis
(Fig. 2), i.e. in four cblD-MMA cell lines, AdoCbl synthesis
increased after transfection with cblD_MLS_ALDH2 from
1% of total cobalamins to only 2.0–3.8% (P ¼ 0.025 in
D003, p.S20X/pS20X; P ¼ 0.146 in D010, p.S20X/p.S20X,
data not shown; P ¼ 0.020 in D008, p.L21IfsX2/
p.C153MfsX10; P ¼ 0.073 in D012, p.A45GfsX15/
p.A45GfsX15). In the other two patients, the increase was
more prominent from ≤1 to 10% (P ¼ 0.004 in D004,
p.R54X/p.L103_S108dup; P ¼ 0.001 in D017, p.N77EfsX5/
p.N77EfsX5) (Fig. 2). In contrast, in three cell lines with
cblD-MMA/HC (D006, p.Y140X/p.Y140X; D007, p.T204_
A232del/p.T204_A232del; D009, p.S228X/p.S228X), trans-
fection with cblD_MLS_ALDH2 led to rescue of AdoCbl syn-
thesis to normal levels. Finally, in control cells, transfection
with cblD_MLS_ALDH2 resulted in a small but not significant
(P ¼ 0.139) increase in AdoCbl synthesis (Fig. 2). Transfection
had no substantial effect on the normal level of MeCbl synthesis
in any of the cblD-MMA cell lines (data not shown).
Figure 1. Effect of optimized MLS on rescue of AdoCbl synthesis in a
cblD-MMA/HC cell line. Transformed fibroblasts of a cblD-MMA/HC
patient (D007, p.F204_A232del/p.F204_A232del) were transfected with a
construct (cblD_MLS_ALDH2) that replaces the 11 amino acids long putative
MLS of MMADHC by the MLS of aldehyde dehydrogenase 2 (ALDH2) and
assayed for adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl) syn-
thesis. Transfections with empty vector (vector only) and wild-type (wt) were
used as controls. Constructs were prepared using pTracer vector and transfec-
tions were made by electroporation. Columns represent the mean and vertical
lines the range of results from seven replicate experiments with single deter-
minations. In a transformed control cell line transfected with an empty vector,
the mean synthesis of AdoCbl was 18% (range 14–24%, n ¼ 7) and that of
MeCbl 51% (range 46–61%).
Figure 2. Transfection studies of cblD-wt and MLS optimized cblD-wt in
various patient cell lines. Adenosylcobalamin (AdoCbl) synthesis in trans-
formed fibroblasts of five cblD-MMA patients (D003, p.S20X/p.S20X;
D008, p.L21IfsX2/p.C153MfsX10; D012, p.A45GfsX15/p.A45GfsX15;
D004, p.R54X/p.L103_S108dup; D017, p.N77EfsX5/p.N77EfsX5), three
cblD-MMA/HC patients (D006, p.Y140X/p.Y140X; D007, p.T204_A232del/
p.T204_A232del; D009, p.S228X/p.S228X) and a control after transfection
with a MMADHC wild-type (cblD-wt) construct and a construct
(cblD_MLS_ALDH2) that replaces the endogenous 11 amino acids long puta-
tive MLS of MMADHC with the MLS of aldehyde dehydrogenase 2
(ALDH2). Transfection with empty vector (vector only) was used as negative
control. Patient D010 with the same genotype as patient D003 (p.S20X/
p.S20X) gave similar results (data not shown). All constructs were prepared
using pTracer vector and transfections were made by electroporation.
Columns represent the mean and vertical lines the range of results from at
least four replicate experiments with single determinations.
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Attempts to increase the level of rescue of AdoCbl synthesis
with the cblD wild-type allele in a cblD-MMA cell line homo-
zygous for p.S20X (D003 or D010) by using another type of
vector (pcDNA3) for transient transfection were not success-
ful. When using stable transfection in a retroviral system
(pBABE), again only a small but statistically significant (P
≤ 0.001) increase in AdoCbl from 1.3 to 3.4% was seen (Sup-
plementary Material, Fig. S2).
MMADHC mRNA expression
Real-time polymerase chain reaction (PCR) showed consider-
able differences in the levels of MMADHC mRNA in cblD cell
lines (Fig. 3A). Clearly reduced levels were obtained in a
patient with the combined cblD-MMA/HC phenotype and
homozygous for a premature termination codon (PTC) in
exon 5 (D006, c.419dupA, p.Y140X), and to a lesser extent
in a patient with an isolated cblD-MMA phenotype compound
heterozygous for a PTC and an inframe duplication in exon 4
(D004, c.160C.T, p.R54X/c.307_324dup, p.L103_S108dup).
However, mRNA levels were not significantly reduced in
other patients with the cblD-MMA phenotype and PTCs in
exon 3 [D003 and D010 (data not shown), homozygous for
c.57_64del, p.S20X; D012, homozygous for c.133dupG,
p.A45GfsX15]; in exons 3 and 5 (D008, c.60insAT,
p.L21IfsX2/c.455dupC, p.C153MfsX10) and in exon 4
(D017, homozygous for c.228dupG, p.N77EfsX5). Normal
mRNA levels were also found in patients with the
cblD-MMA/HC phenotype and homozygous for PTCs in
exon 7 (D009, c.683C.G, p.S228X) or exon 8 (D005,
c.748C.T, p.R250X), or an inframe skipping of exon 7
(D007, c.696+1_4delGTGA, p.T204_A232del). Suppression
of nonsense-mediated mRNA decay (NMD) using emetine
rescued mRNA levels in the two patients with clearly
reduced mRNA levels to normal and increased mRNA levels
in all cell lines tested (Supplementary Material, Fig. S3). In
all other cell lines, the expression varied from 0.6 to 1.4
when compared with that of four control cell lines normalized
to mRNA levels of glyceraldehyde 3-phosphate dehydrogen-
ase (GAPDH) (data not shown). Similar results were obtained
when the mRNA levels were normalized to the mRNA of the
mitochondrial protein MRPL19 (data not shown).
A negative correlation was observed between the mean
levels of expression of MMADHC mRNA and the level of
rescue of AdoCbl synthesis in the different cblD-MMA cell
lines. Thus, the correlation coefficients between mRNA syn-
thesis and AdoCbl rescue were R ¼ 0.89 and R ¼ 0.83 for
transfection with the wild-type and cblD_MLS_ALDH2 con-
struct, respectively. No such correlation was observed in
cblD-MMA/HC cell lines.
MMADHC protein expression
Endogenous production of the MMADHC protein was studied
by immunoprecipitation in crude cell extracts. This showed a
single band of 32.8 kDa corresponding to the full-length cblD
protein in control cells. In cells of patient D003 homozygous
for p.Ser20X, smaller bands of 26.5 and 20.5 kDa correspond-
ing to MMADHC proteins starting at Met62 and Met116,
respectively, were detected (Fig 3B). In cells of patient D017,
homozygous for p.N77EfsX5, only the 20.5 kDa band corre-
sponding to MMADHC starting at Met116 was present. No
MMADHC protein was detected in cell lines D006 and D007
that are homozygous for p.Y140X and p.F204_A232del, re-
spectively.
Figure 3. MMADHC mRNA and protein expression in various mutant and
control cell lines. Relative levels of MMADHC mRNA (A) in fibroblasts of
five cblD-MMA patients (D003, c.57_64del/c.57_64del; D008, c.60insAT/
c.455dupC; D012, c.133dupG/c.133dupG; D004, c,160C.T/c.307_324dup;
D017, c.228dupG/c.228dupG) and four cblD-MMA/HC patients (D006,
c.419dupA/c.419dupA; D009, c.683C.G/c.683C.G; D007, c.696+1_4del/
c.696+1_4del; D005, c.748C.T/c.748C.T) measured by quantitative real-
time PCR. Patient D010 with the same genotype as patient D003
(c.57_64del/c.57_64del) gave similar results (data not shown). mRNA levels
were compared with mean level obtained in four control cell lines and were
normalized to mRNA level of GAPDH. Columns are the mean and vertical
lines the range of triplicate determinations. MMADHC protein expression
(B) in fibroblasts of two representative cblD-MMA patients (D003,
c.57_64del/c.57_64del; D017, c.228dupG/c.228dupG) and two cblD-MMA/
HC patients (D006, c.419dupA/c.419dupA; D007, c.696+1_4del/
c.696+1_4del). Cell extracts were immunoprecipitated with a polyclonal anti-
MMADHC antibody, separated by SDS–PAGE in a 12% polyacrylamide gel
and visualized with a monoclonal anti-MMADHC antibody as described in
Materials and Methods.
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Effect of mutations associated with cblD-MMA on the level
of rescue of AdoCbl synthesis
The negative correlation observed between the level of the
rescue of AdoCbl synthesis and the level of mRNA among the
cblD-MMA cell lines suggests that the endogenous mutant
protein in these cells may affect the ability of the wild-type
protein to produce AdoCbl. We therefore studied the effect of
five cblD-MMA associated mutations on rescue of AdoCbl syn-
thesis by co-transfecting a combined cblD-MMA/HC cell line
(D007, p.F204_A232del/p.F204_A232del) with the wild-type
cDNA containing an optimized MLS (cblD_MLS_ALDH2) to-
gether with each of five constructs carrying cblD-MMA asso-
ciated mutations (Fig. 4). Co-transfection with empty vector,
wild-type and a construct containing the nonsense mutation
c.683C.G/p.S228X that is associated with the cblD-MMA/
HC phenotype were used as controls. When compared with
co-transfection of cblD_MLS_ALDH2 with empty vector,
co-transfection with wild-type construct resulted in a significant
decrease in AdoCbl synthesis from 19% of total cobalamins to
12% (P ≤ 0.001). AdoCbl synthesis after co-transfection with
one of the cblD-MMA-associated mutant alleles (c.160C.T,
p.R.54X) decreased to 11% and did not differ from that with
wild-type (P ¼ 0.655), whereas after co-transfection with four
other cblD-MMA-associated mutant alleles (c.57-64del,
p.S20X; c.60insAT, p.L21IfsX2; c.133dupG, p.A45GfsX15;
c.228dupG, p.N77EfsX5) the decrease was significantly lower
than with the wild-type, i.e. a decrease to 5.1% (P ≤ 0.001),
5.9% (P ¼ 0.001), 8.2% (P ¼ 0.008) and 5.6% (P ≤ 0.001), re-
spectively. Co-transfection with the null-allele p.S228X
showed no effect (P ¼ 0.096). Similar results were obtained
when transfecting cell line D006, homozygous for a truncating
mutation in the middle of the protein (c.419dupA/p.Y140X)
(data not shown).
These findings are in accordance with the variable levels of
mRNA and rescue of AdoCbl synthesis in the different
cblD-MMA cell lines and suggest that these mutant proteins
interfere with the wild-type protein by affecting AdoCbl syn-
thesis to various degrees.
Effect of alternative start codons on synthesis of MeCbl
and AdoCbl
All six patients with the cblD-MMA phenotype have at least
one allele carrying a mutation that leads to premature termin-
ation of translation before the second or third methionine
located at positions 62 and 116, respectively (Table 1). Four
of these are homozygous and the other two are compound het-
erozygous and carry in addition (i) a deletion that leads to a
frameshift and premature termination at amino acid residue
162 (p.C153MfsX10 in D008), and (ii) an in-frame duplication
of the amino acids 103–108 (p.L103_S108dup in D004). Both
mutations are not detectable at the cDNA level but clearly het-
erozygous at the genomic level, suggesting that the
steady-state level of mRNA from these alleles is very low.
Since MeCbl synthesis is completely normal in these patients,
we have speculated that there is reinitiation of translation at a
downstream AUG codon, e.g. at Met62 and/or at Met116.
Both codons are located within a sequence compatible with
the Kozak consensus (3,9).
To test this hypothesis, we prepared constructs with selected
changes in the MMADHC wild-type cDNA, transfected them
into a cblD-MMA/HC cell line (D007, p.F204_A232del/
p.F204_A232del) and investigated the rescue of cobalamin co-
enzyme synthesis. As shown in Figure 5, N-terminal trunca-
tion to either Met62 (Fig. 5, construct 5) or Met116 (Fig. 5,
construct 7), or introduction of a stop codon at position 89
(Fig. 5, construct 9), does not lead to lack of MeCbl synthesis.
In contrast, introduction of a stop codon at position 118
(Fig. 5, construct 10) completely abolishes MeCbl synthesis.
These findings confirm that translation can be initiated either
at Met62 or at Met116, but not downstream of Met116.
Concerning AdoCbl synthesis, as expected there was no
AdoCbl formation with truncation N-terminally to Met62 or
Met116 as these constructs lack a MLS (Fig. 5). However,
introduction of the MLS of ALDH2 N-terminally at Met62
(Fig. 5, construct 6) resulted in significant rescue of AdoCbl
synthesis, whereas no rescue was observed when the MLS
was added N-terminally to Met116 (Fig. 5, construct 8).
This indicates that the sequence between Met62 and Met116
and downstream is essential for mitochondrial AdoCbl synthe-
sis. Thus, the protein truncated N-terminally to Met116 has
lost the dual function being unable to support AdoCbl synthe-
sis but being fully active in MeCbl synthesis.
The removal of possible alternative translation start sites by
mutating Met62 and Met116 to glutamine residues (10)
(Fig. 5, constructs 3 and 4) did not significantly affect the
Figure 4. Effect on AdoCbl synthesis of co-transfection of MLS optimized
cblD-wt together with various mutant cblD-MMA alleles in a cblD-MMA/HC
cell line. AdoCbl synthesis was measured in transformed fibroblasts of a
cblD-MMA/HC patient (D007, p.F204_A232del/p.F204_A232del) after
co-transfection of a wild-type construct (cblD_MLS_ALDH2) in which the
endogenous putative MLS ofMMADHC is replaced by the MLS of aldehyde de-
hydrogenase 2 (ALDH2) together with wild-type (wt) or cblD-MMA-associated
mutant alleles (p.S20X, p.L21IfsX2, p.A45GfsX15, p.R54X, p.N77EfsX5).
Co-transfection together with empty vector (vector only) and with a
cblD-MMA/HC-associated mutant allele (p.S228X) were used as controls. All
constructs were prepared using pTracer vector and transfections were made
by electroporation. Columns represent the mean and vertical lines the range of
results from at least four replicate experiments with single determinations.
1414 Human Molecular Genetics, 2012, Vol. 21, No. 6
synthesis of MeCbl (P ¼ 0.294) or AdoCbl (P ¼ 0.640). This
suggests that initiation of translation at alternative start sites
plays at most a minor role in the wild-type.
DISCUSSION
Our studies provide further evidence for the idea that the
MMADHC protein contains various domains responsible for
(i) targeting the protein towards the mitochondria; (ii)
MeCbl synthesis and (iii) AdoCbl synthesis. Accordingly,
the nature and location of mutations within the protein deter-
mine one of three biochemical phenotypes, i.e. combined
MMA/HC, isolated MMA or isolated HC.
To date, we have identified a total of 17 patients, 5 with a
combined defect and 6 each with isolated MMA or isolated
HC (Table 1). In line with our idea, each patient with
cblD-MMA carries on at least one mutant allele causing a pre-
mature stop toward the N-terminal part of the protein. Import-
antly, one patient (D017) is homozygous for a duplication
leading to a stop codon at position 81 (p.N77EfsX5) which
is downstream from the second (Met62) but upstream from
the third (Met116) initiation codon supporting the idea that
reinitiation of translation can also occur at Met116. All six
patients with cblD-HC carry at least one missense mutation
causing amino acid substitutions toward the C-terminal part
of the protein. Interestingly, these three mutations are
located within a short stretch of 14 amino acids (p.D246G,
p.Y249C, p.L259P). Using expression studies, we have
proven the functional significance of these mutations.
This small region is one of the five putative sites of inter-
action between MMADHC and MMACHC according to
recent phage-display experiments (11). Thus, our data
support the hypothesis that mutations in the C-terminal part
of MMADHC could lead to a defect in the MeCbl pathway
by preventing binding with MMACHC.
Further supporting our concept, three additional reported
patients with cblD-MMA are homozygous for mutations
leading to a premature stop codon N-terminal of Met62 (6).
All five patients with the combined defect carry mutations
that are predicted to lead to premature stop codons C-terminal
of Met116.
Central to the various features of this special protein are
reinitiation of translation at downstream start codons and
both cytosolic and mitochondrial localization. Our studies
conclusively show that a truncated protein lacking the first
115 amino acids is fully capable of MeCbl synthesis. In
support of reinitiation of translation and in line with naturally
occurring mutations in patients, we have shown that truncation
N-terminally to Met62 or Met116, or introduction of a stop
codon at position 89, still allow formation of MeCbl, while
a stop codon after Met116 knocks out the formation of
MeCbl (Fig. 5). In line with our concept, western blot
studies showed formation of protein of the sizes expected
from the position of stop codons and subsequent reinitiation
of translation (Fig. 3B).
Our studies show that AdoCbl synthesis requires targeting
of the cblD protein to the mitochondria (positions 1–61) and
an intact sequence downstream from Met62 (Fig. 5). More
precise identification of the essential sequence for AdoCbl
synthesis requires further studies. Dual localization of proteins
has been shown to be caused by various mechanisms, includ-
ing alternative splicing, initiation codon scan-through, mul-
tiple in-frame start codons, incomplete secretion, reverse
translocation, spontaneous folding and others (12–18). Fur-
thermore, proteins that are localized in both mitochondria
and the cytosol have been shown to be more likely to have a
weak MLS (19). Thus, the nature of the MLS can shift the
balance between mitochondrial and cytosolic localization
Figure 5. Effect of alternative start codons on synthesis of methylcobalamin
(MeCbl) and adenosylcobalamin (AdoCbl). To study possible initiation of trans-
lation from alternative AUG codons, selected changes were introduced into the
wild-type cDNA followed by transfection into immortalized fibroblasts of a
cblD-MMA/HC patient (D007, p.F204_A232del/p.F204_A232del) and assay
of cobalamin coenzyme synthesis. The different constructs used are numbered
from 1 to 10 and the predicted structures of the expressed proteins are schemat-
ically presented by vertical bars. Thus, grey bars represent functionally active
protein, black bars MLS of aldehyde dehydrogenase 2 (ALDH2_MLS) and
white bars functionally inactive polypeptides. Transfection with empty vector
(vector only) and wild-type (wt) were used as controls. Changes were introduced
into wild-type cDNA by site-directed mutagenesis as described in Materials and
Methods. All constructs were prepared using pTracer vector and transfections
were done by electroporation. Columns represent the mean and vertical lines
the range of results from at least four replicate experiments with single determi-
nations.
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(20). Moreover, our studies confirm that the balance between
mitochondrial and cytosolic formation can be strongly influ-
enced by the presence and nature of a MLS. Thus, replacing
the putative endogenous MLS of MMADHC by the MLS of
ALDH2, an established mitochondrial enzyme (21,22), dra-
matically increased AdoCbl formation with a concomitant re-
duction in MeCbl formation (Fig. 1). Finally, the results
obtained with the construct in which possible alternative trans-
lation start sites had been removed in the wild-type by mutat-
ing Met62 and Met116 to glutamine residues demonstrate that
production of shortened isoform is not essential for the pro-
cesses leading to MeCbl or AdoCbl synthesis. Thus, we con-
clude that in wild-type cells a single protein product fulfils
the functions needed for synthesis of both coenzymes and
this is supported by dual localization of MMADHC.
To our surprise, AdoCbl formation could not be rescued in
cblD-MMA cell lines to the same extent as in cblD-MMA/HC
cell lines, even when using the cblD_MLS_ALDH2 construct
(Fig. 2). In considering this lack of rescue, we evaluated
MMADHC mRNA expression and rescue of AdoCbl with the
wild-type and CblD_MLS_ALDH2 construct in five
cblD-MMA cell lines. We observed a negative correlation
between the level of endogenous MMADHC mRNA (Fig. 3A)
and the level of AdoCbl rescue (Fig. 2), suggesting that in
these cell lines the level of endogenous mRNA and/or
MMADHC protein may influence AdoCbl rescue. We speculate
that if MMADHC is part of a complex necessary for the forma-
tion of AdoCbl, a shorter MMADHC protein produced in
cblD-MMA cells due to reinitiation of translation at Met62 or
Met116 could affect formation of functional complexes
thereby reducing AdoCbl synthesis. Another possibility is that
the short polypeptides that are produced in cblD-MMA patients
(from Met1 to the stop codon resulting from the mutation) could
interact with full-length protein or with binding partners located
in the cytosol or at the mitochondrial membrane. In support of
these findings, co-transfection of cblD-MMA/HC cells with
the cblD_MLS_ALDH2 and various cblD-MMA mutant
alleles also show variable rescue of AdoCbl synthesis (Fig. 4).
Again the level of rescue appears to correlate with the level of
endogenous mRNA (Fig. 3A).
Essentially normal amounts of mRNA were observed in
patients D005 (p.R250X/p.R250X) and D009 (p.S228X/
p.S228X). This can be explained by the well-established rule
that PTCs residing in the last or penultimate exon (that is,
they are not followed by more than one exon–exon junction)
generally do not elicit NMD (23). As expected, severely
reduced mRNA levels were found in the cblD-MMA/HC
patient 006 homozygous for a PTC in exon 5 (p.Y140X/
p.Y140X). Regarding the truncating mutations found in the
cblD-MMA cell lines before the second (D003 and D010,
D008, D0012, D004) or third (D017) start codon would all
fulfill the rules of a PTC eliciting NMD, but instead have
(near) normal levels of mRNA (Fig. 3). We can only speculate
about the immunity of these cblD-MMA cell lines to NMD. A
possible explanation would be that translation reinitiation
downstream of a PTC inhibits NMD (24), indicating that
PTC recognition by translating ribosomes is not sufficient
for NMD, and that NMD depends on events that are subse-
quent to translation termination and are precluded by reinitia-
tion (23).
Interaction of MMADHC with MMACHC may play a role
in the regulation of the balance between AdoCbl and MeCbl
synthesis. Thus, we observed that co-transfection of the cblC
gene with cblD wild-type cDNA in cblD-MMA/HC or
cblD-MMA cell lines doubled the level of AdoCbl synthesis
with less effect on MeCbl synthesis, compared with cblD wild-
type alone (unpublished results). This is supported by the
finding that MMADHC acts as a binding partner for
MMACHC both in vitro and in vivo (11).
In summary, our findings suggest that under physiological
conditions, there is a delicate balance of intracellular localiza-
tion of MMADHC and that this balance is influenced by the
efficacy of the MLS, supporting the concept that the cblD
protein acts as a branch point in intracellular cobalamin traf-
ficking. Our data indicate that the sequence after Met116 is
sufficient for MeCbl synthesis, whereas the sequence from
Met62 downstream is required for AdoCbl synthesis. We
propose the existence of one single protein with two different
functional domains that interact with either cytosolic or mito-
chondrial targets. Further studies on interactions with possible
partner proteins and determination of the 3-D structure of
MMADHC and sub-cellular localization will help further elu-




Fibroblasts were obtained for diagnostic purposes with
informed consent from the patients or their parents and refer-
ring clinicians approved the use of the cells for our investiga-
tion of the origin of the disease. Fibroblasts were routinely
grown in Earl’s minimal essential medium (Amimed, Basel,
Switzerland) supplemented with 10% fetal bovine serum
(Amimed) as described earlier (5). Fibroblasts were trans-
formed by transfection with pRNS1 (25) using electroporation
as previously described (3).
Mutation analysis
Genomic DNA and total RNA were extracted from cultured
patient fibroblasts using the QIAamp DNA Mini Kit and
RNeasy Kit (Qiagen, Hombrechtikon, Switzerland), respect-
ively. For mutation analysis, genomic DNA and cDNA
synthesized from total RNA by reverse transcription (RT–
PCR) were amplified by PCR using specific primers as
described earlier (3). To confirm mutations identified in
RT–PCR products, the corresponding exons were amplified
by PCR from genomic DNA using flanking intronic primers
and were sequenced by the ABI BigDye method (Applied Bio-
systems, Rotkreuz, Switzerland). All mutations were checked
for their correct designation using ‘mutalyzer’ (www.muta
lyzer.nl) according to the guidelines of the Human Genome
Variation Society.
Preparation of constructs for transfection
Constructs containing the MMADHC wild-type and mutant
cDNA were prepared in mammalian expression vectors as
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described earlier (26). Shortly, cDNA was produced from total
RNA by reverse transcription using the Titan One Tube RT–
PCR Kit (Roche, Basel, Switzerland), cloned into
pCR-Blunt-II-TOPO (Invitrogen, Basel, Switzerland), sub-
cloned into pTracer-CMV2 (Invitrogen) at the EcoRI site
and propagated in Escherichia coli DH5a competent cells
(Invitrogen). Plasmids for transfections were isolated using
the QIAfilter Plasmid Maxi Kit (Qiagen). Introduction of the
sequence of base pairs corresponding to the MLS of ALDH2
(MLRAAARFGPRLGRRLLSAAATQA) (27) into wild-type
MMADHC cDNA at different positions and production of
truncated and mutant MMADHC cDNAs was achieved using
site-directed mutagenesis and appropriate oligonucleotides
(Supplementary Material, Table S1). All PCR reactions
were carried out using Hot Gyro Polymerase (Solis
Biodyne, Tartu, Estonia). PCR products were cloned into
pTracer-CMV2, as described above. All constructs were
sequenced to verify that they contained the indicated changes.
Transfection studies
Constructs containing wild-type and different mutant cDNA
sequences in pTracer-CMV2 were transfected transiently
into transformed patient and control fibroblasts by electropor-
ation as described earlier (3). Rescue of cellular function was
tested by measuring the synthesis of MeCbl and/or AdoCbl
from [57Co]cyanocobalamin, as described previously (5).
Real-time PCR
cDNA was synthesized from total RNA using the TaqMan
Reverse Transcription Reagent (Applied Biosystems). Analysis
of the abundance of theMMADHCmRNA was performed using
the TaqMan Universal PCR Master Mix (Applied Biosystems)
according to the manufacturer’s recommendations, except that
the total reaction volume was reduced to 10 ml. The TaqMan
probes (Applied Biosystems) used were Hs00739517_g1
(MMADHC) and as controls Hs00608519_m1 (MRPL19) and
Hs99999905_m1 (GAPDH).
Western blot studies
Fibroblasts from control and CblD patients were lysed with
radio immuno precipitation assay buffer (Invitrogen), immu-
noprecipitated with proteinG-sepharose (Invitrogen) and a
polyclonal mouse anti-human MMADHC antibody (Biogenes,
Berlin, Germany). Proteins were separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS–PAGE) on a
12% gel, transferred to polyvinylidene difluoride membranes,
blocked at room temperature for 1 h with 1% bovine serum
albumin in phosphate buffered saline containing 0.1%
Tween 20 and incubated overnight with a monoclonal mouse
anti-human MMADHC antibody (AMSBio, Lugano, Switzer-
land). Visualization of protein bands was performed using a
donkey anti-rabbit antibody conjugated with horseradish per-
oxidase (Jackson ImmunoResearch, Newmarket, UK) and
SuperSignal reagent according to the manufacturer’s instruc-
tions (Perbio, Lausanne, Switzerland). As protein molecular
size marker, we used Kaleidoscope Precision Plus (BioRad,
Reinach, Switzerland).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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